Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Hillstream BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, Hillstream aims to acquire a clinical stage asset, AV104 (nalmefene), an opioid antagonist, but first it intends to seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis with primary biliar...
Brand Name : AV104
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 11, 2023
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Hillstream BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?